EyePoint Raises $306M Runway, Phase 3 DME Dosing and Mid-2026 Wet AMD Data
EyePoint ended 2025 with $306 million in cash and investments, funding operations into Q4 2027, while posting a fourth-quarter net loss of $67.6 million on $0.62 million of revenue versus $31.4 million for full-year 2025. The company has dosed first patients in pivotal Phase 3 DME trials and expects top-line wet AMD data beginning mid-2026.
1. Financial Results
In the fourth quarter, EyePoint reported a net loss of $67.6 million, or $0.81 per share, on revenue of $0.62 million. Full-year 2025 results showed a net loss of $232 million, or $3.17 per share, on $31.4 million in revenue.
2. Cash Position and Runway
At year-end, the company held $306 million in cash and investments following a $173 million financing in October, providing funding for operations into the fourth quarter of 2027.
3. DURAVYU Clinical Progress
EyePoint dosed the first patients in pivotal Phase 3 trials for diabetic macular edema and continues blinded reviews in two Phase 3 wet AMD studies, expecting top-line data beginning mid-2026 for its six-month dosing intravitreal therapy.
4. Safety Profile and Oversight
Across more than 190 patients in early trials, DURAVYU has shown no new safety signals, with approximately 1% intraocular inflammation and cataract and floaters rates comparable to control. Independent Data Monitoring Committees have confirmed a consistent safety profile.